uploads///Graph

Analysts’ Recommendations for AbbVie in January

By

Updated

ABBV’s price movements

On January 10, AbbVie (ABBV) closed at $88.20, 0.44% higher than its previous closing price. The company closed at a premium of 13.81% to its 52-week low price of $77.50 and a discount of 29.92% to its 52-week high price of $125.86. On January 10, AbbVie’s market cap was $132.91 billion. The company was trading at a trailing PE ratio of 17.37x and a forward PE ratio of 10.12x.

Based on its closing price on January 10, the company had reported returns of 2.21% in the last week, 0.67% in the last month, and -6.74% in the last quarter. AbbVie had also reported returns of -7.12% in the last half year, -12.01% in the last year, and -4.33% YTD (year-to-date).

Article continues below advertisement

Based on its closing price on January 10, the broader healthcare sector represented by the Health Care Select Sector SPDR ETF (XLV) had reported returns of 4.85% in the last week, -3.73% in the last month, and -7.30% in the last quarter. XLV had also reported returns of 1.44% in the last half year, 1.84% in the last year, and 1.17% YTD.

AbbVie has been mostly underperforming the broader healthcare sector represented by XLV in 2018 and 2019.

Analysts’ recommendations and target prices

The 12-month consensus analyst recommendation for AbbVie on January 11 was a “hold.” The 12-month consensus target price for the company was $99.28, 12.56% higher than its closing price on January 10. The highest target price estimate for the company was $135, and the lowest target price estimate was $71.

Of the 19 analysts covering AbbVie on January 10, three analysts rated the company as a “strong buy,” four analysts rated it as a “buy,” nine rated it as a “hold,” two rated it as a “sell,” and one rated it as a “strong sell.”

In the next article, we’ll compare the revenue growth prospects of Merck & Co. (MRK) and AbbVie in greater detail.

Advertisement

More From Market Realist